Xiang Ming-Que, Huang Ai-Long, Tang Ni, Xiao Yu-Jun, Yan Ge, He Tong-Chuan
Institute for Viral Hepatitis, Chongqing University of Medical sciences, Chongqing 400010, China.
Zhonghua Yi Xue Za Zhi. 2003 Jul 10;83(13):1156-60.
To investigate the expression of recombinant IkappaBalphaM (AdIkappaBalphaM) in human hepatocarcinoma cell line HepG(2) and the inhibiting effect to NF-kappaB.
To test the virus titer in 293 cells and the infective efficiency virus titer in HepG(2) cells with GFP and limited dilution method, then to assay the IkappaBalphaM expression of recombinant adenovirus and the alteration after induction of TNF-alpha in 293 cells and HepG(2) by Western blotting, furthermore, to observe NF-kappaB activity in HepG(2) before and after treatment of TNF-alpha by EMSA.
The titer of AdIkappaBalphaM is 2 x 10(8) pfu/L, MOI equals to 20. AdIkappaBalphaM could be expressed stably and efficiently in HepG(2) and will not degrade by induction of TNF-alpha; but IkappaBalpha in the uninfection cell as well as AdIkappaBalpha control was increased at first and then decreased. EMSA demonstrated that the infected cells showed no activation of NF-kappaB before and after the treatment of TNF-alpha, but the cells of uninfected and infected with AdIkappaBalpha appeared excessive activation of NF-kappaB.
AdIkappaBalphaM could be amplified in 293 cell and effectively infect to target cells HepG(2), and could be expressed stably in cells, and wouldn't be degrade with treatment of TNF-alpha, also it can effectually inhibit the excessive activation of NF-kappaB in HepG(2). The result of our research indicates the theoretical value of IkappaBalphaM as a super inhibitor, inhibition activity of NF-kappaB with IkappaBalphaM super-suppressor aided with routine anti-tumor therapy would become an effective method.
研究重组IκBαM(AdIκBαM)在人肝癌细胞系HepG(2)中的表达及其对NF-κB的抑制作用。
采用绿色荧光蛋白(GFP)和有限稀释法检测293细胞中病毒滴度及HepG(2)细胞中病毒感染效率滴度,然后用蛋白质免疫印迹法检测重组腺病毒在293细胞和HepG(2)细胞中IκBαM的表达及肿瘤坏死因子-α(TNF-α)诱导后的变化,此外,通过电泳迁移率变动分析(EMSA)观察TNF-α处理前后HepG(2)细胞中NF-κB的活性。
AdIκBαM滴度为2×10(8) pfu/L,感染复数(MOI)等于20。AdIκBαM能在HepG(2)细胞中稳定高效表达,且不会因TNF-α诱导而降解;但未感染细胞以及AdIκBα对照中的IκBα起初升高后降低。EMSA表明,感染细胞在TNF-α处理前后未显示NF-κB激活,但未感染和感染AdIκBα的细胞出现NF-κB过度激活。
AdIκBαM可在293细胞中扩增并有效感染靶细胞HepG(2),能在细胞中稳定表达,不会因TNF-α处理而降解,还能有效抑制HepG(2)细胞中NF-κB的过度激活。我们的研究结果表明IκBαM作为一种超级抑制剂的理论价值,用IκBαM超级抑制剂辅助常规抗肿瘤治疗抑制NF-κB活性将成为一种有效的方法。